KisunlaTM (donanemab-azbt) , pronounced kih-SUHN-lah, is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of ...

The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...

While there's no cure yet for Alzheimer's, researchers are finally making more progress in better understanding the disease ...

FDA could also establish a more clear and transparent structure for interactions between agency staff and companies, which ...

Aduhelm generated hopes in the public and medical community alike when it was developed several years ago under the name aducanumab by Biogen Inc., but disappointing results from initial trials of the ...

Biogen and Eisai have already filed for approval of their amyloid-targeting antibody aducanumab, and while some analysts see the evidence for the drug as somewhat shaky, it has a chance of ...

the abject failure of Alzheimer's drug and former blockbuster hope Aduhelm (aducanumab) in the market, setbacks in its R&D pipeline, and leadership changes. Analysts at Jefferies suggested earlier ...

Cheryl, 75, has lived with Alzheimer’s disease for nearly five years, but it hasn’t all been bleak. John, 76, said he had some hope for about 18 months when Cheryl was enrolled in a clinical trial for ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

Why did Latrepirdine Fail in Phase III Studies? There are several plausible explanations for the failure of latrepirdine in Phase III trials despite promising Phase II data. The three most likely ...

The WVU Rockefeller Neuroscience Institute is providing patients greater statewide and regional access to a groundbreaking ...